Home   Contact   Careers   En español   

BETA Archive: 1996-2001

Spring 2001
  • Monitoring Anti-HIV Medicines: What Is the FDA’s Role?
  • Dual Protease Inhibitors Gain Ground
  • HIV-Related Fatigue
  • Botswana: Context of the Epidemic
Winter 2001
  • The Persistent Epidemic: HIV Among Men Who Have Sex with Men
  • Anal Neoplasia: A Growing Concern
  • HIV/AIDS Pricing Report: Setting Objectives: Is There a Political Will?
  • Lessons Learned from Natural History Studies in Women
Autumn 2000
  • Sexually Transmitted Diseases and HIV-Related Risks
  • Restoring Immunity in HIV Disease
  • Approaches to Interrupting HAART for the Treatment of HIV Infection
  • Human Rights and the AIDS Crisis: The Debate over Resources
Summer 2000
  • The Global HIV/AIDS Epidemic
  • Feasible Microbicides Remain Elusive
  • Issues in HIV Postexposure Prophylaxis
  • The Wide-Ranging Effects of Nucleoside Analogs: A Look at Mitochondrial Toxicity

Spring 2000

  • HIV Persists Despite HAART
  • Adverse Effects Associated with Antiretroviral Therapy
  • Structured Treatment Interruption: Future Protocol or Wishful Thinking?
  • Special Report on HIV as the Cause of AIDS

Year-End 1999

  • Antiretroviral Pharmacology: Issues and Management
  • Natural History and Treatment of Hepatitis C
  • Status Report on HIV Vaccine Development
  • HIV/AIDS in Adolescence
  • HIV Skin Complications in the Age of HAART

Summer 1999

  • Jay A. Levy, MD: HIV/AIDS Research at the Millennium
  • Sexual Transmission in the Era of New Treatments
  • Genotypic and Phenotypic Resistance Testing
  • Global Perspectives on Nutrition and HIV Infection: A Special Report

April 1999

  • HAART Attack: Metabolic Disorders During Long-Term Antiretroviral Therapy
  • Current Challenges to HIV Research
  • Volunteering for Clinical Trials

January 1999

  • The Challenge of Adherence to Highly Active Anti-Retroviral Therapy
  • Body Fat Change: More than Lipodystrophy
  • Opportunistic Infections: Is It Safe to Stop Prophylaxis?
  • Highlights from Recent Conferences

October 1998

  • Coverage of the 12th World AIDS Conference
  • Protease-Sparing Combination Regimens
  • Tuberculosis

July 1998

  • Unusual Body Changes: A Possible Side Effect of Anti-HIV Treatment?
  • Blood Cell Deficiencies
  • Advertising for AIDS Drugs
  • HIV and Children: the Nutrition Story

April 1998

  • DNA and Other Technologies for HIV Vaccines
  • Herbs for HIV
  • Side Effects Associated with Anti-HIV Drugs
  • You and Your Doctor: Ideas on Managing One of the Most Important Relationships in Your Life

Jan. 1998

  • Adherence and the HIV Community
  • Resistance to Antiretroviral Drugs
  • Hepatitis
  • AIDS-Related Lymphoma
  • Complementary and Alternative Medicine

Sept. 1997

  • DMP-266 and Adefovir Dipivoxil
  • Protease Inhibitor Drug Interactions
  • Adherence
  • Progressive Multifocal Leuko-
    encephalopathy
  • Chinese Medicine for HIV Positive Women
  • June 1997

  • New HIV Treatment Guidelines
  • Nausea/Diarrhea/Food Safety
  • Women and HIV Conference Highlights
  • March 1997

  • 3-Drug Therapy Reduces AIDS Progression and Death
  • Chemokines and HIV
  • Psychiatric Aspects of HIV
  • Peripheral Neuropathy
  • Retroviruses Conference Highlights
  • Dec. 1996

  • 1592 - Most Important AIDS Drug in the Pipeline
  • Mycobacterium avium Complex
  • AIDS Dementia Complex
  • Perinatal HIV Transmission
  • ICAAC Conference Highlights
  • Sept. 1996

  • Highlights from the International Conference on AIDS
  • Anabolic Steroids and HIV-Related Wasting
  • HIV Vaccines
  • Advocacy Issues: Viral Load Access/Medical Marijuana/HMO Patient Rights
  • Treating HIV During Pregnancy
  • June 1996

  • Viral Load Testing
  • Pneumonia
  • Non-Nucleoside Reverse Transcriptase Inhibitor Drugs
  • HIV/AIDS in Children
  • Cervical Intraepithelial Neoplasia
  • Page last updated: 9/17/2007


    995 Market Street Ste 200, San Francisco CA 94103
    feedback@sfaf.org • 415/487-3000 • Privacy Policy